Table 3.

Case-reports and open-label studies examining terbinafine use in non-dermatophyte infections

Organism	Site	Dosing regimen	Outcome	Reference
Aspergillus spp.	toenail	500 mg/day (pulse: 1 wk/mos) 3 months	clinical and mycological cure (88%)	168
Aspergillus flavus	musclea	250 mg daily 13 weeks	resolution	169
Aspergillus sydowii	toenail	500 mg/day (pulse: 1 wk/mos)b 3 months	failure	128
Aspergillus ustus	skina	not providedc 11 months	resolution	170
Cladosporium carrionii	skin	500 mg daily 4–12 months	cure or clinical improvement (83%–100%)	171, 172
Curvularia lunata	heart valve (endocarditis)	125 mg twice dailyd,e 7 years	tissue mycologically negative	173
Fonsecaea monophora	skin	250 mg dailyb 7–10 weeks	clinical and mycological cure	174
Fonsecaea pedrosoi	skin	500 mg daily 4–12 months	cure or clinical improvement (83%–100%)	171,172
Paecilomyces lilacinus	cornea (keratitis)	250 mg once dailyb,c 10–12 weeks	resolution	175, 176
Paracoccidoides brasiliensis	perineum/scrotum	250 mg twice daily 6 months	resolution	177
Piedra hortae	scalp	250 mg once daily 6 weeks	effective	178
Phialphora parasitica	disseminateda	125 mg twice daily 2 months	drug discontinued	179
Sporothix schenckii	cutaneous/subcutaneous	250 mg twice daily range: 8–37 weeks	success	180, 181

^aNotes: Patient immunocompromised or immunosuppressed;

^bConcurrent treatment with itraconazole;

^cConcurrent treatment with voriconazole;

^dConcurrent treatment with amphotericin B;

^eConcurrent treatment with ketoconazole.